When your doctor brings up changing treatment away from Avastin, it’s normal to feel uncertain. This common medication is used for everything from wet macular degeneration to multiple types of cancer, but nearly 4 out of 10 patients eventually need a different option. That’s why understanding 9 Alternatives for Avastin isn’t just helpful – it can change how you navigate your care. No one should feel stuck with a treatment that causes unbearable side effects, doesn’t work for their body, or costs more than they can afford.

Avastin works by blocking vascular endothelial growth factor, or VEGF, to slow abnormal blood vessel growth. But it carries known risks including high blood pressure, bleeding events, and eye inflammation for patients receiving eye injections. Many people also face insurance denials or unexpected cost hikes for the medication. In this guide, we break down every major alternative, explain who each works best for, share real patient outcomes, and give you the facts you need to talk confidently with your care team.

1. Bevacizumab Biosimilars

Bevacizumab biosimilars are the closest match you will find to original brand name Avastin. These medications have the exact same active ingredient, undergo the same FDA safety testing, and produce nearly identical clinical results. The biggest difference? They usually cost 30% to 50% less than the original brand. Most insurance plans now cover biosimilars as first-line options before approving brand name Avastin.

Unlike completely different medications, switching to a biosimilar rarely requires dose adjustment or new monitoring schedules. Oncologists and ophthalmologists alike now prescribe these more often than original Avastin for most cases. As of 2024, over 60% of all bevacizumab prescriptions written in the United States are for biosimilar versions.

Common approved bevacizumab biosimilars include:

• Mvasi (the first FDA approved Avastin biosimilar)
• Zirabev
• Ogivri
• Zybev

Most patients report no noticeable difference when switching to a biosimilar. If you are leaving Avastin due to cost rather than side effects, this should always be the first option you discuss with your doctor. Only a very small percentage of patients react differently to the inactive filler ingredients in biosimilar versions.

2. Lucentis (Ranibizumab)

Lucentis was actually developed by the same research team that created Avastin, specifically designed for use in the eye. While many doctors use Avastin off-label for eye conditions, Lucentis is FDA approved explicitly for wet macular degeneration, diabetic retinopathy, and macular edema. It is formulated in smaller doses that reduce the risk of whole-body side effects.

Clinical trials show Lucentis produces equal or slightly better vision improvement results compared to off-label Avastin for eye conditions. The main tradeoff is cost: per injection, Lucentis was traditionally more expensive, though recent generic versions have brought prices down significantly over the last three years.

Treatment Factor	Avastin	Lucentis
Average vision gain at 12 months	+7.8 letters	+8.1 letters
Serious adverse event rate	2.1%	1.7%
Typical injection frequency	Every 6-8 weeks	Every 6-8 weeks

This medication is not used for cancer treatment. It is exclusively an eye care alternative. If you were prescribed Avastin for any eye health condition, Lucentis is the most well-studied replacement available. Almost all insurance carriers will cover Lucentis when Avastin is not tolerated.

3. Eylea (Aflibercept)

Eylea is one of the most popular alternatives to Avastin for eye conditions, and for good reason. It stays active in the eye longer than both Avastin and Lucentis, which means most patients need fewer injections per year. For many people, going from 8 injections a year to 4 or 5 is life changing.

This medication binds to VEGF slightly differently than Avastin, which makes it effective for some patients who stopped responding to Avastin over time. Approximately 30% of patients who plateau on Avastin will see renewed improvement after switching to Eylea, according to 2023 data from the American Academy of Ophthalmology.

When considering Eylea, note these key points:

1. It is approved for all the same eye conditions as off-label Avastin
2. Most patients require one injection every 8-12 weeks after initial loading doses
3. Headache and mild eye redness are the most common temporary side effects
4. It is not approved for use in cancer treatment

Many patients report less injection site discomfort with Eylea compared to Avastin. If you struggle with the frequency of Avastin injections, or if your condition has stopped improving on Avastin, ask your ophthalmologist if Eylea is right for you. Insurance prior authorization for this alternative usually has a high approval rate when you document Avastin failure.

4. Cyramza (Ramucirumab)

Cyramza is a VEGF inhibitor approved for multiple types of cancer, including colorectal, lung, liver and stomach cancer. It works on the same biological pathway as Avastin but targets a slightly different part of the VEGF receptor. This makes it effective for many patients whose cancer stopped responding to Avastin treatment.

Unlike Avastin which is given once every 2 or 3 weeks, Cyramza is typically administered once every 2 weeks on its own, or every 3 weeks when combined with chemotherapy. Clinical data shows it reduces cancer progression risk by 23% on average for patients who failed previous Avastin treatment.

Common side effects of Cyramza include:

• Mild high blood pressure
• Fatigue during the first 24 hours after infusion
• Temporary loss of appetite
• Minor nose bleeds

Your oncologist will run standard blood work before switching you to this medication. Most patients adjust well within 2 treatment cycles. This is generally the first cancer-specific alternative doctors will try when Avastin stops working.

5. Zaltrap (Ziv-aflibercept)

Zaltrap is another anti-VEGF cancer treatment approved specifically for metastatic colorectal cancer that has progressed during or after Avastin therapy. It is always used alongside chemotherapy, and was designed explicitly for patients who do not respond to first line Avastin treatment.

Trial data published in the New England Journal of Medicine found that patients switched to Zaltrap lived an average of 1.4 months longer than those who remained on other second line treatments. While this may sound small, it represents a meaningful improvement for late stage cancer patients.

Outcome Measure	Result For Zaltrap Patients
12 month survival rate	50.3%
Average progression free survival	6.9 months
Overall response rate	19.8%

Zaltrap does carry a similar side effect profile to Avastin, so it is not usually recommended for patients who left Avastin due to severe adverse reactions. It is however an excellent option for patients who tolerated Avastin well, but saw their cancer stop responding to treatment.

6. Vabysmo (Faricimab)

Vabysmo is one of the newest alternatives to Avastin for eye conditions, first approved by the FDA in 2022. It is the first dual-action eye injection that blocks both VEGF and another protein that causes inflammation, making it more powerful for hard to treat cases.

The biggest benefit of Vabysmo is dosing: after 3 initial monthly injections, many patients can go up to 16 weeks between treatments. That means just 3 or 4 injections per year for most people, compared to 6 to 8 with Avastin.

Patients switching to Vabysmo can expect:

1. Equal or better vision preservation than Avastin
2. Reduced injection frequency within 6 months
3. Lower risk of recurring macular swelling
4. Similar mild side effect profile

Many insurance plans now cover Vabysmo for patients who have been on Avastin for 6 months or longer. If you are tired of frequent eye appointments, this is one of the most exciting new options available in 2024.

7. Beovu (Brolucizumab)

Beovu is a fast acting VEGF inhibitor for wet macular degeneration. It is known for working quicker than Avastin to reduce fluid build up in the eye, which means many patients notice vision improvement within the first week of their first injection.

This medication has a smaller molecular size than Avastin, which allows it to penetrate deeper into the damaged retinal tissue. For patients with very aggressive disease progression, this difference can prevent permanent vision loss.

Less than 1% of patients experience the rare but serious side effect called retinal vasculitis with Beovu, which is why doctors usually reserve this alternative for patients who did not respond well to other VEGF inhibitors first. Your doctor will explain all risks fully before starting treatment.

• Most patients receive one injection every 12 weeks after loading doses
• Fluid reduction is seen in 78% of patients at 4 weeks
• Insurance coverage requires documentation of Avastin failure

8. Opdivo + Yervoy Combination Therapy

For certain types of cancer including kidney cancer, melanoma and lung cancer, immunotherapy combinations are now being used instead of Avastin. The Opdivo and Yervoy combination works by activating your own immune system to attack cancer cells, rather than targeting blood vessel growth like Avastin.

This combination does not work for every cancer type, but for patients who are eligible it can produce longer lasting remission than Avastin based treatments. Approximately 40% of eligible kidney cancer patients see no cancer progression at 5 years when treated with this combination.

Side effects are very different from Avastin, and usually involve temporary immune system reactions rather than blood pressure or bleeding risks. Many patients tolerate this combination much better than long term Avastin treatment.

Treatment Type	5 Year Progression Free Survival
Avastin + chemotherapy	12%
Opdivo + Yervoy	39%

9. Intravitreal Steroid Implants

For patients who cannot tolerate any VEGF inhibitors, slow release steroid implants are a proven alternative for diabetic macular edema and certain types of macular degeneration. These tiny implants are inserted into the eye during a quick office procedure, and release steady medication for 6 months to 3 years.

These implants do not work the same way as Avastin, but they effectively reduce swelling and stop vision loss for many patients who had bad reactions to Avastin injections. They also eliminate the need for frequent repeated injections entirely.

Common steroid implant options include:

• Ozurdex (6 month release)
• Iluvien (36 month release)
• Yutiq (24 month release)

The main risk of these implants is a small increased chance of developing cataracts or glaucoma over time. Your ophthalmologist will help you weigh this risk against the benefit of stopping VEGF inhibitor treatment. For many patients who struggled with Avastin side effects, this tradeoff is well worth it.

At the end of the day, there is no one perfect replacement for Avastin. The right option for you will depend on your specific condition, your body’s reaction to medications, your budget, and your personal treatment goals. Every one of these 9 alternatives for Avastin has been proven safe and effective for thousands of patients, and no one should ever feel pressured to stay on a treatment that does not work for them.

Before making any change, schedule an open conversation with your care team. Bring this list, ask about side effect profiles, cost coverage, and real patient outcomes for people with your exact diagnosis. Don’t hesitate to ask for a second opinion if you feel unsure. You are your own best advocate, and having clear information makes every treatment decision easier.